Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy

J. R. Chapman, H. Valantine, J. Albanell, W. A. Arns, J. M. Campistol, H. Eisen, M. Frigerio, H. Lehmkuhl, R. Marcen, R. Morris, B. Nashan, J. Pascual, E. Pohanka, J. Segovia, A. Zuckermann

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting "Proliferation signal inhibitors in transplantation: questions at the cutting edge," this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)2937-2950
Number of pages14
JournalTransplantation proceedings
Volume39
Issue number10
DOIs
StatePublished - Dec 1 2007

Fingerprint

Immunosuppressive Agents
Transplantation
Allografts
Graft Survival
Cardiovascular Infections
Therapeutics
Tissue Survival
Sirolimus
Heart Transplantation
Kidney Transplantation
Immunosuppression
Cardiovascular Diseases
Survival Rate
Everolimus
Morbidity
Physicians
Transplants
Mortality
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Chapman, J. R. ; Valantine, H. ; Albanell, J. ; Arns, W. A. ; Campistol, J. M. ; Eisen, H. ; Frigerio, M. ; Lehmkuhl, H. ; Marcen, R. ; Morris, R. ; Nashan, B. ; Pascual, J. ; Pohanka, E. ; Segovia, J. ; Zuckermann, A. / Proliferation Signal Inhibitors in Transplantation : Questions at the Cutting Edge of Everolimus Therapy. In: Transplantation proceedings. 2007 ; Vol. 39, No. 10. pp. 2937-2950.
@article{37005998b08e453eb6451a7fe82673bb,
title = "Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy",
abstract = "While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting {"}Proliferation signal inhibitors in transplantation: questions at the cutting edge,{"} this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.",
author = "Chapman, {J. R.} and H. Valantine and J. Albanell and Arns, {W. A.} and Campistol, {J. M.} and H. Eisen and M. Frigerio and H. Lehmkuhl and R. Marcen and R. Morris and B. Nashan and J. Pascual and E. Pohanka and J. Segovia and A. Zuckermann",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2007.09.008",
language = "English (US)",
volume = "39",
pages = "2937--2950",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

Chapman, JR, Valantine, H, Albanell, J, Arns, WA, Campistol, JM, Eisen, H, Frigerio, M, Lehmkuhl, H, Marcen, R, Morris, R, Nashan, B, Pascual, J, Pohanka, E, Segovia, J & Zuckermann, A 2007, 'Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy', Transplantation proceedings, vol. 39, no. 10, pp. 2937-2950. https://doi.org/10.1016/j.transproceed.2007.09.008

Proliferation Signal Inhibitors in Transplantation : Questions at the Cutting Edge of Everolimus Therapy. / Chapman, J. R.; Valantine, H.; Albanell, J.; Arns, W. A.; Campistol, J. M.; Eisen, H.; Frigerio, M.; Lehmkuhl, H.; Marcen, R.; Morris, R.; Nashan, B.; Pascual, J.; Pohanka, E.; Segovia, J.; Zuckermann, A.

In: Transplantation proceedings, Vol. 39, No. 10, 01.12.2007, p. 2937-2950.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proliferation Signal Inhibitors in Transplantation

T2 - Questions at the Cutting Edge of Everolimus Therapy

AU - Chapman, J. R.

AU - Valantine, H.

AU - Albanell, J.

AU - Arns, W. A.

AU - Campistol, J. M.

AU - Eisen, H.

AU - Frigerio, M.

AU - Lehmkuhl, H.

AU - Marcen, R.

AU - Morris, R.

AU - Nashan, B.

AU - Pascual, J.

AU - Pohanka, E.

AU - Segovia, J.

AU - Zuckermann, A.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting "Proliferation signal inhibitors in transplantation: questions at the cutting edge," this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.

AB - While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting "Proliferation signal inhibitors in transplantation: questions at the cutting edge," this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=37149004201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149004201&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2007.09.008

DO - 10.1016/j.transproceed.2007.09.008

M3 - Article

C2 - 18089298

AN - SCOPUS:37149004201

VL - 39

SP - 2937

EP - 2950

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -